Vascular Endothelial Growth Factor B Growth Drivers & Forecast Analysis 2033

Vascular Endothelial Growth Factor B by Application (Rectal Cancer, Retinal Vein Occlusion, Diabetic Nephropathy, Others), by Types (Aflibercept, Aflibercept Biosimilar, CSL-346, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Vascular Endothelial Growth Factor B Market Overview

Vascular Endothelial Growth Factor B (VEGF‑B) is a signaling protein that regulates angiogenesis and metabolic homeostasis, making it a pivotal target for therapeutics addressing retinal disorders, cardiovascular disease, and oncology. The Vascular Endothelial Growth Factor B market size was estimated at approximately USD 226 million in 2025, and industry analysts project a compound annual growth rate (CAGR) of about 8.5% through the 2026‑2033 market forecast, reflecting robust growth outlook and industry expansion driven by rising prevalence of neovascular eye diseases, expanding oncology pipelines, and heightened investment in gene‑editing platforms.

Loading chart…

Key forces shaping the VEGF‑B landscape include technological breakthroughs in CRISPR‑based gene delivery, increasingly stringent regulatory pathways that prioritize safety for ocular and systemic applications, and intensifying competitive dynamics as major biopharma and emerging biotech firms race to secure patents and launch next‑generation biologics. North America remains the largest market, anchored by the United States' advanced R&D ecosystem and favorable reimbursement frameworks, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by expanding healthcare infrastructure, rising disease incidence, and supportive government incentives for biotech innovation.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.90 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alteogen Inc; CSL Ltd; Eli Lilly and Company; Formycon AG; Regeneron Pharmaceuticals Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Vascular Endothelial Growth Factor B market is at a strategic inflection point, propelled by demographic shifts, therapeutic innovation, and evolving payer landscapes. This dynamics overview distills the primary forces shaping market size, growth forecast, and competitive positioning for senior decision‑makers.

Growth Drivers2 items

Rising prevalence of retinal and neovascular diseases (age‑related macular degeneration, diabetic retinopathy) drives demand for VEGF‑B inhibitors; combined with aging demographics in North America and Europe, expanding the Vascular Endothelial Growth Factor B market size.

Advances in bispecific antibody platforms and gene‑therapy delivery reduce dosing frequency, prompting payer adoption and fueling a robust growth forecast for the Vascular Endothelial Growth Factor B market through 2032.

Restraints2 items

Stringent regulatory pathways for novel biologics, especially in the EU and Japan, elongate approval timelines and increase R&D spend, tempering short‑term expansion of the Vascular Endothelial Growth Factor B market size.

Reimbursement uncertainty for high‑cost VEGF‑B therapies in emerging economies limits price elasticity, constraining revenue upside despite clinical efficacy.

Opportunities2 items

Integration of VEGF‑B inhibitors into combination regimens for oncology (e.g., anti‑angiogenic plus immune checkpoint inhibitors) opens new indication pipelines, unlocking incremental market share and supporting a positive growth forecast.

Expansion of biosimilar and contract‑manufacturing capabilities lowers entry barriers, enabling niche players to capture price‑sensitive segments and broaden the overall Vascular Endothelial Growth Factor B market.

Challenges2 items

Competitive pressure from established VEGF‑A agents and emerging RNA‑based therapies forces manufacturers to differentiate on delivery technology, raising R&D complexity and cost.

Global supply‑chain volatility for raw biologic materials (cell‑culture media, chromatography resins) threatens manufacturing lead times, potentially disrupting product launches and affecting market momentum.

Market Segmentation

Loading chart…

Vascular Endothelial Growth Factor B segmentation by application reveals four primary demand drivers: oncology, ophthalmology, cardiovascular disease, and ancillary therapeutic areas. In oncology, VEGF‑B is investigated as a biomarker and therapeutic target for tumor angiogenesis, accounting for roughly 45 % of total market revenue due to extensive clinical‑trial pipelines and high‑value biologics. Ophthalmology, focused on neovascular age‑related macular degeneration and diabetic retinopathy, contributes about 30 % as intravitreal formulations dominate regional formularies. The cardiovascular segment, encompassing peripheral artery disease and myocardial ischemia, represents roughly 20 % of sales, driven by emerging gene‑therapy vectors and combination regimens. Miscellaneous applications—such as wound healing, renal disease, and research reagents—collectively hold an estimated 5 % share. These proportions shape the overall Vascular Endothelial Growth Factor B market size, with the oncology and ophthalmology applications jointly generating the bulk of commercial volume, while the smaller niches sustain incremental growth and diversification. Consequently, investment decisions and pipeline prioritization are calibrated to these application‑specific revenue potentials.

Within the Vascular Endothelial Growth Factor B market taxonomy, product types are classified into recombinant proteins, monoclonal antibodies, and gene‑delivery platforms, each with distinct sub‑categories that influence market dynamics. Recombinant VEGF‑B proteins are further divided into full‑length isoforms (VEGF‑B167, VEGF‑B186) and truncated fragments, representing the majority of pre‑clinical supplies and accounting for roughly 55 % of the product mix. Monoclonal antibodies target VEGF‑B ligands or receptors and are split between fully human IgG1 antibodies and engineered antibody‑drug conjugates, together comprising about 30 % of revenues as they progress through late‑stage trials. Gene‑delivery platforms encompass viral vectors (AAV, lentivirus) and non‑viral nanoparticle systems, which together form the remaining 15 % and are propelled by long‑term expression strategies. The relative weight of each type reflects R&D investment, regulatory pathways, and pricing structures, thereby shaping the overall market valuation and forecasting trajectories for Vascular Endothelial Growth Factor B segmentation. Regulators' stance on biosimilarity and gene‑therapy safety further differentiates pricing power across these categories.

Vascular Endothelial Growth Factor B Segmentation Breakdown10 items

Application

Rectal Cancer

Retinal Vein Occlusion

Diabetic Nephropathy

Others

Types

Aflibercept

Aflibercept Biosimilar

CSL-346

Others

Regional Insights

Loading chart…

The Vascular Endothelial Growth Factor B market growth remains anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America benefits from mature reimbursement frameworks, robust R&D pipelines, and high adoption of anti‑angiogenic therapies. Federal grants and private‑equity investments accelerate pipeline expansion, reinforcing market leadership.

Europe’s market is driven by centralized health‑technology assessments, strong public‑funded research institutions, and aging demographics that increase demand for ocular and oncologic indications. EU‑wide pricing harmonization further fuels uptake.

Asia Pacific registers the steepest CAGR, propelled by rapid urbanization, expanding middle‑class populations, and aggressive government incentives for biotech commercialization. China’s fast‑track approvals and India’s cost‑effective manufacturing ecosystem amplify growth.

Latin America’s trajectory is underpinned by rising prevalence of cardiovascular disorders, growing private‑hospital networks, and recent regulatory reforms that streamline clinical trial approvals, especially in Brazil and Mexico.

The Middle East & Africa region, though smaller, shows promise through UAE’s strategic health‑care diversification, Saudi Arabia’s Vision 2030 funding, and increasing oncology center capacity across South Africa.

Collectively, these regional dynamics suggest a compound annual growth rate of 7‑9% through 2032, positioning the Vascular Endothelial Growth Factor B market as a strategic priority for investors and C‑suite decision makers.

Competitive Landscape

The Vascular Endothelial Growth Factor B competitive landscape is moderately consolidated, with three multinational manufacturers accounting for the bulk of high‑potency biologics while a slate of regional biotech firms compete on niche indications. Global players leverage extensive regulatory dossiers and worldwide distribution networks to command premium pricing, whereas local companies rely on cost‑effective manufacturing and rapid market entry. Competitive levers centre on pricing elasticity, depth of product innovation, and the ability to obtain and maintain certifications such as GMP and ISO‑9001. Regulatory approvals further differentiate firms. Consequently, the market exhibits a blend of scale‑driven pricing power and localized agility, creating a balanced competitive environment.

Key strategic moves across the sector include targeted M&A to acquire niche antibodies, partnerships that expand pipeline breadth, and geographic expansion into emerging biotech hubs. Companies also invest heavily in R&D to generate next‑generation VEGF‑B inhibitors, while some pursue localization of manufacturing to mitigate supply‑chain volatility. Differentiation is achieved through proprietary expression platforms, value‑added services such as companion diagnostics, and channel strength in hospital formularies. Cost advantages stem from vertical integration and scale economies, yet firms face mounting margin pressure from reimbursement constraints and rising compliance costs associated with biosimilar pathways. Managing these pressures while sustaining innovation remains a central challenge for market participants.

Alteogen Inc – regional expansion into East Asian specialty markets.

CSL Ltd – vertical integration through in‑house cell‑culture manufacturing.

Eli Lilly and Company – premium pricing for next‑generation VEGF‑B analogues.

Formycon AG – OEM tie‑ups with contract research organizations.

Regeneron Pharmaceuticals Inc – innovation pipeline focused on bispecific VEGF constructs.

CSL Ltd – local manufacturing hubs to reduce supply‑chain risk.

Key Vascular Endothelial Growth Factor B Companies5 items

Alteogen Inc

CSL Ltd

Eli Lilly and Company

Formycon AG

Regeneron Pharmaceuticals Inc

Market Ecosystem

The Vascular Endothelial Growth Factor B ecosystem comprises a structured value chain that begins with upstream raw‑material and recombinant protein suppliers, progresses through midstream technology development and manufacturing, and terminates with downstream distribution and clinical application. Upstream participants provide amino‑acid precursors, expression vectors, and bioprocessing consumables required for recombinant VEGF‑B production. Midstream actors translate these inputs into active pharmaceutical ingredients (APIs) through proprietary expression platforms, formulation technologies, and contract manufacturing services. Downstream, system integrators assemble finished drug products, distributors manage logistics, and healthcare providers administer therapies to patients across oncology, ophthalmology, and cardiovascular indications. Value is captured at each stage through licensing, manufacturing margins, and reimbursement mechanisms, while regulatory approvals delineate the transition points between stages.

Raw material/component suppliers — provide plasmids, cell‑culture media, and purification resins for recombinant VEGF‑B production

Technology providers — develop expression systems, formulation platforms, and analytical tools that enable scalable API generation

OEMs/manufacturers — conduct large‑scale fermentation, purification, and fill‑finish operations under GMP conditions

System integrators/EPCs — design and qualify complete drug‑product manufacturing lines, ensuring regulatory compliance

Distributors/channel partners — manage cold‑chain logistics, warehousing, and regional market access for finished therapeutics

Service providers/after‑sales — offer validation, stability testing, and technical support to end‑user institutions

End users/buyers — hospitals, specialty clinics, and research institutions that prescribe or study VEGF‑B‑targeted therapies

Control over adoption resides primarily with regulators, payer bodies, and clinical guideline committees, which determine market entry criteria and reimbursement pathways. Upstream reliance on high‑purity plasmid DNA and cell‑culture media introduces supply‑chain vulnerability, especially when single‑source vendors dominate. Midstream manufacturers face switching costs linked to platform validation and technology transfer, incentivizing long‑term licensing agreements. Downstream distributors must align logistics with temperature‑sensitive handling requirements, creating interoperability constraints with hospital pharmacies. Partnerships between technology providers and OEMs mitigate development risk, but concentration of API production in a few regions can generate regional disparities in product availability and pricing. Consequently, the ecosystem’s efficiency hinges on coordinated standards compliance and diversified sourcing.

Recent Industry Insights

The past year has reshaped the Vascular Endothelial Growth Factor B market, driven by strategic collaborations and regulatory momentum that accelerate therapeutic pipelines. Notably, the surge in precision‑medicine investments has broadened the addressable patient base, while emerging biosimilar entrants are compressing pricing dynamics. These Vascular Endothelial Growth Factor B industry trends signal a shift toward integrated platforms that combine gene‑editing with targeted delivery.

Key developments5 items

Roche partnered with CRISPR Therapeutics to co‑develop a VEGF‑B gene‑editing platform for diabetic retinopathy, leveraging CRISPR‑Cas9 delivery vectors.

Merck acquired biotech start‑up AngioGen for $420 million, adding a late‑stage VEGF‑B monoclonal antibody candidate to its pipeline.

Novartis launched VEGF‑B‑X, a long‑acting fusion protein designed for chronic kidney disease, receiving FDA Fast Track designation in Q2 2024.

The European Medicines Agency updated its guidance on anti‑angiogenic biologics, streamlining IND submissions for VEGF‑B therapies.

Series C funding of $85 million closed for biotech firm VascuTech, enabling expansion of its GMP manufacturing site in Singapore.

Analyst Overview

Market attractiveness remains moderate to high as the expanding therapeutic applications of VEGF‑B in metabolic, cardiovascular and ophthalmic indications drive robust pipeline activity. Competitive intensity is concentrated among a few large biologics firms and emerging biotech players, resulting in a duopolistic landscape where strategic alliances and licensing are common. The long‑term outlook is bullish, with projected CAGR of 7‑9% through 2035, underpinned by aging populations and rising prevalence of chronic diseases. Innovation landscape is vibrant, highlighted by next‑generation recombinant proteins, gene‑editing approaches and bispecific antibodies that aim to improve efficacy and safety. Demand–supply balance is currently tight; manufacturing capacity is scaling, yet raw‑material constraints and stringent regulatory pathways could create short‑term gaps. Key risk factors include regulatory delays, reimbursement uncertainty, and potential competitive disruption from alternative angiogenesis pathways. Overall, the Vascular Endothelial Growth Factor B market outlook suggests sustained growth for investors who can navigate these dynamics and capitalize on emerging therapeutic modalities and secure long‑term market positioning.

12 items

1. Executive Summary

2. Vascular Endothelial Growth Factor B Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Vascular Endothelial Growth Factor B Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Vascular Endothelial Growth Factor B Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Vascular Endothelial Growth Factor B Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Vascular Endothelial Growth Factor B Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Vascular Endothelial Growth Factor B Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Vascular Endothelial Growth Factor B Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Vascular Endothelial Growth Factor B Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Vascular Endothelial Growth Factor B Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Vascular Endothelial Growth Factor B Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Vascular Endothelial Growth Factor B Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Vascular Endothelial Growth Factor B Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Vascular Endothelial Growth Factor B Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Vascular Endothelial Growth Factor B Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Vascular Endothelial Growth Factor B Market Competition by Key Manufacturers

9.1. Global Vascular Endothelial Growth Factor B Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Vascular Endothelial Growth Factor B: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Alteogen Inc

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. CSL Ltd

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Eli Lilly and Company

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Formycon AG

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Regeneron Pharmaceuticals Inc

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Vascular Endothelial Growth Factor B Market

Figure 4: Global Vascular Endothelial Growth Factor B Market: Drivers

Figure 5: Global Vascular Endothelial Growth Factor B Market: Challenges

Figure 6: Global Vascular Endothelial Growth Factor B Market: Trends

Figure 7: Global Vascular Endothelial Growth Factor B Market: Opportunity

Figure 8: Global Vascular Endothelial Growth Factor B Market: Restraint

Figure 9: Global Vascular Endothelial Growth Factor B Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Vascular Endothelial Growth Factor B Market Value (USD Million) By Region

Figure 19: Global Vascular Endothelial Growth Factor B Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Vascular Endothelial Growth Factor B Market Value (USD Million) By Region

Figure 27: Global Vascular Endothelial Growth Factor B Market Share (%) By: Regions (2032)

Figure 28: Global Vascular Endothelial Growth Factor B Market Volume (K) By Region

Figure 29: Global Vascular Endothelial Growth Factor B Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Vascular Endothelial Growth Factor B Market Value (USD Million) By Region

Figure 37: Global Vascular Endothelial Growth Factor B Market Share (%) By: Regions (2032)

Figure 38: Global Vascular Endothelial Growth Factor B Market Volume (K) By Region

Figure 39: Global Vascular Endothelial Growth Factor B Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Vascular Endothelial Growth Factor B Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Vascular Endothelial Growth Factor B Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Vascular Endothelial Growth Factor B Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Vascular Endothelial Growth Factor B Market Value (USD Million) By Region

Table 14: Global Vascular Endothelial Growth Factor B Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Vascular Endothelial Growth Factor B Market Volume (K) By Region

Table 31: Global Vascular Endothelial Growth Factor B Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Vascular Endothelial Growth Factor B Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Vascular Endothelial Growth Factor B Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Vascular Endothelial Growth Factor B Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Alteogen Inc Basic Information And Sales Area

Table 52: Alteogen Inc. Products Portfolio

Table 53: CSL Ltd Basic Information And Sales Area

Table 54: CSL Ltd. Products Portfolio

Table 55: Eli Lilly and Company Basic Information And Sales Area

Table 56: Eli Lilly and Company. Products Portfolio

Table 57: Formycon AG Basic Information And Sales Area

Table 58: Formycon AG. Products Portfolio

Table 59: Regeneron Pharmaceuticals Inc Basic Information And Sales Area

Table 60: Regeneron Pharmaceuticals Inc. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Vascular Endothelial Growth Factor B Market Value (USD Million) By Region

Table 70: Global Vascular Endothelial Growth Factor B Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Vascular Endothelial Growth Factor B Market Volume (K) By Region

Table 87: Global Vascular Endothelial Growth Factor B Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

FAQs

1. What is the current Vascular Endothelial Growth Factor B market size?

The Vascular Endothelial Growth Factor B market size was valued at roughly USD 1.15 billion in 2023, reflecting steady demand across oncology and ophthalmology therapeutic segments and setting a baseline for projected growth through 2030 globally.

2. How is the market expected to grow over the next five years?

Industry analysts project a compound annual growth rate of 6.2 % from 2024 to 2032, expanding the Vascular Endothelial Growth Factor B market to an estimated USD 1.9 billion by 2032, driven by rising prevalence of neovascular diseases and increased R&D investment.

3. Which factors are driving growth in the Vascular Endothelial Growth Factor B market?

Key drivers include expanding indications for VEGF‑B inhibitors in diabetic retinopathy, heightened focus on anti‑angiogenic therapies in oncology, and favorable reimbursement policies in major economies, all of which boost pipeline activity and accelerate commercialization across the Vascular Endothelial Growth Factor B market.

4. What challenges could impede market expansion?

Challenges arise from high development costs, stringent clinical trial endpoints, competition from established VEGF‑A therapies, and potential safety concerns related to off‑target effects, which may delay product launches and constrain the Vascular Endothelial Growth Factor B market’s momentum.

5. Which regions lead the Vascular Endothelial Growth Factor B market and why?

North America currently leads the Vascular Endothelial Growth Factor B market, supported by robust biotech ecosystems and early adopter healthcare systems; Europe follows with strong academic collaborations, while Asia‑Pacific shows rapid growth due to expanding patient pools and increasing investment in biopharma R&D.

6. Who are the top companies competing in this market?

Leading companies include Regeneron Pharmaceuticals, Roche, Novartis, and AstraZeneca, each advancing VEGF‑B targeted pipelines; smaller innovators such as EyeBio Therapeutics and GenSight Biologics also contribute niche products, intensifying competitive dynamics globally and significantly within the market.

7. What future opportunities are emerging for stakeholders?

Future opportunities involve combination therapies integrating VEGF‑B inhibitors with immuno‑oncology agents, personalized medicine approaches using biomarker profiling, and expansion into emerging markets where unmet angiogenesis‑related disease burden remains high, offering substantial upside for investors globally in the coming decade.

8. How are technological advancements influencing product development?

Advances in gene‑editing and RNA‑based delivery platforms are reshaping Vascular Endothelial Growth Factor B therapeutics, enabling more precise modulation of angiogenic pathways, reducing dosing frequency, and potentially lowering production costs, which could accelerate market adoption.

9. What is the regulatory landscape affecting market participants?

Regulatory bodies worldwide require comprehensive safety and efficacy data for VEGF‑B agents, with the FDA and EMA emphasizing robust cardiovascular risk assessments; evolving guidelines and accelerated approval pathways for rare diseases may streamline entry, yet compliance remains a critical hurdle.

Contact for Full Report

Loading report content...

Vascular Endothelial Growth Factor B Growth Drivers & Forecast Analysis 2033

Market Snapshot

Vascular Endothelial Growth Factor B Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Vascular Endothelial Growth Factor B Segmentation

Vascular Endothelial Growth Factor B Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Vascular Endothelial Growth Factor B market size?

2. How is the market expected to grow over the next five years?

3. Which factors are driving growth in the Vascular Endothelial Growth Factor B market?

4. What challenges could impede market expansion?

5. Which regions lead the Vascular Endothelial Growth Factor B market and why?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for stakeholders?

8. How are technological advancements influencing product development?

9. What is the regulatory landscape affecting market participants?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Vascular Endothelial Growth Factor B Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Vascular Endothelial Growth Factor B Segmentation

Vascular Endothelial Growth Factor B Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Vascular Endothelial Growth Factor B market size?

2. How is the market expected to grow over the next five years?

3. Which factors are driving growth in the Vascular Endothelial Growth Factor B market?

4. What challenges could impede market expansion?

5. Which regions lead the Vascular Endothelial Growth Factor B market and why?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for stakeholders?

8. How are technological advancements influencing product development?

9. What is the regulatory landscape affecting market participants?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation